Cargando…

IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway

SIMPLE SUMMARY: The insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase (RTK) widely expressed in many cancers, including the pediatric cancer neuroblastoma. Aberrant activation of the anaplastic lymphoma kinase (ALK) RTK by activating point mutations or amplification is iden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Jikui, Borenäs, Marcus, Xiong, Junfeng, Lai, Wei-Yun, Palmer, Ruth H., Hallberg, Bengt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563084/ https://www.ncbi.nlm.nih.gov/pubmed/37686528 http://dx.doi.org/10.3390/cancers15174252

Ejemplares similares

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
por: Cervantes-Madrid, Diana, et al.
Publicado: (2019)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
por: Guan, Jikui, et al.
Publicado: (2017)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

Chromosome Imbalances in Neuroblastoma—Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future
por: Guan, Jikui, et al.
Publicado: (2021)

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
por: Huang, Hao, et al.
Publicado: (2021)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells
por: Siaw, Joachim T., et al.
Publicado: (2021)

Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment
por: Mazot, Pierre, et al.
Publicado: (2012)

Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016)

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
por: Sattu, Kamaraj, et al.
Publicado: (2013)

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
por: Moore, Nathan F., et al.
Publicado: (2014)

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent
por: Guan, Jikui, et al.
Publicado: (2016)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
por: Witek, Barbara, et al.
Publicado: (2015)

Novel Agents Targeting the IGF-1R/PI3K Pathway Impair Cell Proliferation and Survival in Subsets of Medulloblastoma and Neuroblastoma
por: Wojtalla, Anna, et al.
Publicado: (2012)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
por: Mus, Liselot M., et al.
Publicado: (2020)

RSC96 Schwann Cell Proliferation and Survival Induced by Dilong through PI3K/Akt Signaling Mediated by IGF-I
por: Chang, Yung-Ming, et al.
Publicado: (2011)

ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells
por: Fadeev, Andrey, et al.
Publicado: (2018)

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
por: Szydzik, Joanna, et al.
Publicado: (2021)

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

5′ ALK Amplification in Neuroblastoma: A Case Report
por: Akhavanfard, Sara, et al.
Publicado: (2021)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
por: Chuang, Tzu-Po, et al.
Publicado: (2023)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
por: Treis, Diana, et al.
Publicado: (2022)

miR-181d promotes cell proliferation via the IGF1/PI3K/AKT axis in glioma
por: Tang, Dong, et al.
Publicado: (2020)

miR-365 inhibits duck myoblast proliferation by targeting IGF-I via PI3K/Akt pathway
por: Sun, Wenqiang, et al.
Publicado: (2019)

BCL11A Facilitates Cell Proliferation and Metastasis in Neuroblastoma via Regulating the PI3K/Akt Signaling Pathway
por: Jin, Qianya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_toe9hv9bhajm6n9ec5ruaik2ul